Cargando…

Hypoxia-activated prodrugs: paths forward in the era of personalised medicine

Tumour hypoxia has been pursued as a cancer drug target for over 30 years, most notably using bioreductive (hypoxia-activated) prodrugs that target antineoplastic agents to low-oxygen tumour compartments. Despite compelling evidence linking hypoxia with treatment resistance and adverse prognosis, a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hunter, Francis W, Wouters, Bradly G, Wilson, William R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Minireview
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4865974/ https://www.ncbi.nlm.nih.gov/pubmed/27070712 http://dx.doi.org/10.1038/bjc.2016.79

Ejemplares similares

The genetics of gout: towards personalised medicine?
por: Dalbeth, Nicola, et al.
Publicado: (2017)

Pharmacogenomics in the era of personalised medicine
por: White, Cassandra, et al.
Publicado: (2022)

Gene expression profiling of gliomas: merging genomic and histopathological classification for personalised therapy
por: Vitucci, M, et al.
Publicado: (2011)

Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedside
por: Boisguérin, V, et al.
Publicado: (2014)

Prediction and personalised treatment of atrial fibrillation—stroke prevention: consolidated position paper of CVD professionals
por: Helms, Thomas M, et al.
Publicado: (2014)

Lung cancer screening: the way forward
por: Field, J K, et al.
Publicado: (2008)

The fork'ed path to mitosis
por: Jorgensen, Paul, et al.
Publicado: (2000)

Studies Towards Hypoxia-Activated Prodrugs of PARP Inhibitors
por: Dickson, Benjamin D., et al.
Publicado: (2019)

Regulation of Wound Healing and Fibrosis by Hypoxia and Hypoxia-Inducible Factor-1
por: Ruthenborg, Robin J, et al.
Publicado: (2014)

Nitroaromatic Hypoxia-Activated Prodrugs for Cancer Therapy
por: Denny, William A.
Publicado: (2022)

Design of Optimized Hypoxia-Activated Prodrugs Using Pharmacokinetic/Pharmacodynamic Modeling
por: Foehrenbacher, Annika, et al.
Publicado: (2013)

Food allergy in children—the current status and the way forward
por: Elghoudi, Ahmed, et al.
Publicado: (2022)

Canonical Wnt signaling: high-throughput RNAi widens the path
por: Brown, Anthony MC
Publicado: (2005)

Targeting Hypoxia: Hypoxia-Activated Prodrugs in Cancer Therapy
por: Li, Yue, et al.
Publicado: (2021)

Moving Forward: Recent Developments for the Ferret Biomedical Research Model
por: Albrecht, Randy A., et al.
Publicado: (2018)

The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104
por: Foehrenbacher, Annika, et al.
Publicado: (2013)

Assessing the origin of species in the genomic era
por: Moyle, Leonie C
Publicado: (2005)

Liver injury in the era of COVID-19
por: Cichoż-Lach, Halina, et al.
Publicado: (2021)

Hypoxia inducible factors in cancer stem cells
por: Heddleston, J M, et al.
Publicado: (2010)

New role for ceramide in hypoxia and insulin resistance
por: Xia, Qing-Song, et al.
Publicado: (2020)

Forward genetics in Tribolium castaneum: opening new avenues of research in arthropod biology
por: Peel, Andrew D
Publicado: (2009)

Diabetes self-care in primary health facilities in India - challenges and the way forward
por: Basu, Saurav, et al.
Publicado: (2019)

Host-pathogen studies in the post-genomic era
por: Kellam, Paul
Publicado: (2000)

Cholestatic liver diseases: An era of emerging therapies
por: Samant, Hrishikesh, et al.
Publicado: (2019)

Lager-brewing yeasts in the era of modern genetics
por: Gorter de Vries, Arthur R, et al.
Publicado: (2019)

Colorectal cancer screening in the COVID-19 era
por: Kadakuntla, Anusri, et al.
Publicado: (2021)

Explorations into the Effect of meso‐Substituents in Tricarbocyanine Dyes: A Path to Diverse Biomolecular Probes and Materials
por: Exner, Rüdiger M., et al.
Publicado: (2020)

Surgical intervention for acute pancreatitis in the COVID-19 era
por: Su, Yu-Jang, et al.
Publicado: (2022)

Hypoxia-activated prodrugs and redox-responsive nanocarriers
por: Zeng, Yun, et al.
Publicado: (2018)

Reconciling art and science in the era of personalised medicine: the legacy of Georges Canguilhem
por: Contino, Gianmarco
Publicado: (2023)

Cyclic di‐nucleotides: new era for small molecules as adjuvants
por: Libanova, Rimma, et al.
Publicado: (2012)

Recent advances in triple negative breast cancer: the immunotherapy era
por: Marra, Antonio, et al.
Publicado: (2019)

Liver disease in the era of COVID-19: Is the worst yet to come?
por: Mikolasevic, Ivana, et al.
Publicado: (2021)

Omics era in type 2 diabetes: From childhood to adulthood
por: Passaro, Antonio Paride, et al.
Publicado: (2021)

Expanding indications for liver transplantation in the era of liver transplant oncology
por: Panayotova, Guergana, et al.
Publicado: (2021)

Beta receptor blocker therapy for the elderly in the COVID-19 era
por: Santillo, Elpidio, et al.
Publicado: (2022)

Recent advances in the management of autoimmune pancreatitis in the era of artificial intelligence
por: Mack, Sahar, et al.
Publicado: (2022)

Liver function in transgender persons: Challenges in the COVID-19 era
por: Milionis, Charalampos, et al.
Publicado: (2023)

Bioelectronic medicine: updates, challenges and paths forward
por: Pavlov, Valentin A., et al.
Publicado: (2019)

The Hypoxia-Activated Prodrug TH-302: Exploiting Hypoxia in Cancer Therapy
por: Li, Yue, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_luets7ed5ks1i4j9rq4jtdkdlg